• Shuttle Pharmaceuticals filed a Form 12b-25, delaying its Form 10-Q for the quarter ended June 30, 2026.
• Management cited an inability to compile all required disclosure information without unreasonable effort or expense.
• Filing targeted by the fifth calendar day after the prescribed due date.
• Notice flagged expected significant results changes, including R&D expense down 95% to $0.1 million.
• Legal and professional expenses rose 112%; general and administrative expense fell 15% to $2 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-038790), on August 17, 2026, and is solely responsible for the information contained therein.